drugset / Trial / NCT07227818
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.
Timeline
- Start
- 2025-12-16
- Primary completion
- 2029-07
- Completion
- 2029-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NBI-1117568 | Unknown | — | Oral |